Drug Trial Radar · NCT05110144
Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough
Last checked: Nov 20, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Nov 1, 2021
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with refractory chronic cough (RCC)
Conditions
- Refractory Chronic Cough
Interventions
Duloxetine 30 MGDrug
30mg orally for 4 weeks
Duloxetine 60 MGDrug
60mg orally for 4 weeks
Amitriptyline 25 MGDrug
25 mg orally for 4 weeks
Amitriptyline 50 MGDrug
50 mg orally for 4 weeks
Placebo 30 MGDrug
30mg tablet with no active study ingredient for 4 weeks
Placebo 60 MGDrug
60mg tablet with no active study ingredient for 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in awake objective cough frequency (at 4 & 8 weeks)Time frame: 4 weeks, 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.